About Pernix
Pernix is a Healthcare company based in The Woodlands (United States) founded in 1997, and was acquired by Currax in May 2019. Pharmaceutical company manufacturing and marketing drugs for pediatric market. Pernix has raised $99 million across 2 funding rounds from investors including Currax. Pernix has completed 2 acquisitions, including Cypress Pharmaceutical and Somaxon. Its focus areas include Diversified Pharmaceuticals. Its legal entity is PERNIX THERAPEUTICS HOLDINGS, INC.
Company details
Pernix Therapeutics was founded in 1997 and is based in The Woodlands, United States. Operations center on the sales, marketing, and development of branded and generic drugs for the pediatric sector. Products address allergy, upper respiratory conditions including congestion and cough, antibiotics, and dermatology needs like head lice and contact dermatitis treatments. The pipeline encompasses the launched Silenor OTC, phase 4 trials for Silenor arousability, and research-stage Treximet.
- Headquarters The Woodlands, United States
- Stage Acquired
- SectorsHealthcare
- Website pernixtx.com
- Social LinkedIn X
- Acquired by Currax (May 2019)
- Legal Name Pernix Therapeutics Holdings, Inc.
- Annual Revenue$146.07 M (USD)4as on Dec 31, 2017
- Net Profit-$77.14 M (USD)55as on Dec 31, 2017
- EBITDA$16.76 M (USD)131as on Dec 31, 2017
- Total Equity Funding$99M (USD)
in 2 rounds
- Latest Funding Round$65M (USD), Private Equity Round
Feb 2014
- Investors
- Investments & AcquisitionsCypress Pharmaceutical
& 1 more
- Acquired byCurrax
(May 2019)
Funding Insights of Pernix
Pernix has successfully raised a total of $99M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $65 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $99M
- Total Rounds 2
- Last Round Private Equity Round — $65M
- First Round $34M
(Jan 2013)
All 2 funding rounds of Pernix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2014 | $65M | Private Equity Round | – | – | – |
| Jan 2013 | $34M | Private Equity Round | – | – | – |
1 investors in total: 1 institutional.
Investors in Pernix
Pernix has secured backing from 1 investor. Prominent investors backing the company include Currax.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Currax Pharmaceuticals is engaged in distributing life-changing medications worldwide. | curraxpharma.com | Brentwood, United States |
Investor details for Pernix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pernix
Pernix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cypress Pharmaceutical and Somaxon.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Health and beauty information and product reviews are provided. | somaxon.com | San Diego, United States | 2003 | Dec 2012 | $25M | |
A variety of generic and branded pharmaceutical formulations are manufactured. | cypressrx.com | Madison Heights, United States | 1993 | Nov 2012 | $97M |
Complete acquisition details for Pernix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pernix
7 dated milestones of Pernix across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Pernix is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Cypress Pharmaceutical.
- Acquisition Acquires Somaxon.
- Funding First funding round of $34.0M.
- Funding Latest funding round, Private Equity Round, of $65.0M.
- Exit Acquired by Currax.
Web traffic of Pernix
Websites that share an audience with Pernix (pernixtx.com).
Websites whose visitors overlap most with Pernix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| collegiumpharma.com | 100% | 13.5K | #1,457,207 | View details | |
| shire.com | 100% | 1.4K | #14,679,892 | View details | |
| shionogi.com | 99% | 164.2K | #248,020 | View details | |
| kusumhealthcare.com | 99% | 1.5K | #12,063,494 | View details | |
| landson.co.id | 61% | #9,108,859 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Pernix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Pernix (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pernix
Complete news archive for Pernix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pernix
Pernix was founded in 1997 and raised its 1st funding round 16 years after it was founded.
Pernix is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Pernix is a funded company, having raised a total of $99M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $34M, raised on Jan 2013.
Annual revenue of Pernix is $146.07M as on Dec 31, 2017.
Pernix Therapeutics was founded in 1997 and is based in The Woodlands, United States. Operations center on the sales, marketing, and development of branded and generic drugs for the pediatric sector. Products address allergy, upper respiratory conditions including congestion and cough, antibiotics, and dermatology needs like head lice and contact dermatitis treatments. The pipeline encompasses the launched Silenor OTC, phase 4 trials for Silenor arousability, and research-stage Treximet.
Pernix has made 2 acquisitions, including Cypress Pharmaceutical, and Somaxon.
Pernix has 1 investor. Key investors include Currax.
Pernix operates through Pernix Therapeutics Holdings, Inc..
Yes. Pernix was acquired by Currax in May 2019.